XSTOFLUI
Market cap1mUSD
Dec 23, Last price
0.03SEK
1D
-19.90%
1Q
-56.92%
IPO
-99.82%
Name
Fluicell AB
Chart & Performance
P/E
—
P/S
4.75
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
68.07%
Rev. gr., 5y
22.18%
Revenues
3m
+2.68%
Net income
-27m
L+23.58%
CFO
-27m
L+29.39%
Profile
Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 3,338 2.68% | 3,251 24.94% | 2,602 -43.86% | ||||||
Cost of revenue | 1,600 | 663 | 10,657 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 1,738 | 2,588 | (8,055) | ||||||
NOPBT Margin | 52.07% | 79.61% | |||||||
Operating Taxes | (120) | 27 | |||||||
Tax Rate | |||||||||
NOPAT | 1,738 | 2,708 | (8,082) | ||||||
Net income | (26,554) 23.58% | (21,487) -1.07% | (21,720) 19.64% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 3,871 | 25,942 | 23,202 | ||||||
BB yield | -5.46% | -14.74% | -1.95% | ||||||
| Debt | |||||||||
Debt current | (1,014) | (1,358) | |||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 858 | ||||||||
Net debt | (2,763) | (25,471) | (22,052) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (27,227) | (21,043) | (18,640) | ||||||
CAPEX | (1,136) | (772) | |||||||
Cash from investing activities | (1,136) | (772) | |||||||
Cash from financing activities | 5,533 | 25,942 | 21,306 | ||||||
FCF | 2,737 | 2,242 | (8,316) | ||||||
| Balance | |||||||||
Cash | 2,763 | 24,457 | 20,694 | ||||||
Long term investments | |||||||||
Excess cash | 2,596 | 24,294 | 20,564 | ||||||
Stockholders' equity | (136,251) | (109,997) | (89,619) | ||||||
Invested Capital | 136,676 | 129,908 | 105,128 | ||||||
ROIC | 1.30% | 2.30% | |||||||
ROCE | 408.94% | 13.00% | |||||||
| EV | |||||||||
Common stock shares outstanding | 112,158 | 67,696 | 59,208 | ||||||
Price | 0.63 -75.69% | 2.60 -87.06% | 20.10 -1.47% | ||||||
Market cap | 70,884 -59.73% | 176,009 -85.21% | 1,190,076 5.96% | ||||||
EV | 68,121 | 150,538 | 1,168,024 | ||||||
EBITDA | 2,348 | 3,308 | (7,467) | ||||||
EV/EBITDA | 29.01 | 45.51 | |||||||
Interest | 30 | 238 | 27 | ||||||
Interest/NOPBT | 1.73% | 9.20% | |||||||